Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-08-19
2008-10-28
Carr, Deborah D (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S086000
Reexamination Certificate
active
07442719
ABSTRACT:
The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.
REFERENCES:
patent: 2140800 (1938-12-01), Leemans
patent: 3994974 (1976-11-01), Murakami et al.
patent: 4730008 (1988-03-01), Skidmore et al.
patent: 4853381 (1989-08-01), Finch et al.
patent: 4853382 (1989-08-01), Skidmore et al.
patent: 4908386 (1990-03-01), Finch et al.
patent: 4937268 (1990-06-01), Skidmore et al.
patent: 4963564 (1990-10-01), Skidmore et al.
patent: 4990505 (1991-02-01), Skidmore et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 4997986 (1991-03-01), Mitchell et al.
patent: 5066678 (1991-11-01), Skidmore et al.
patent: 5091422 (1992-02-01), Skidmore et al.
patent: 5099068 (1992-03-01), Mitchell et al.
patent: 5109023 (1992-04-01), Mitchell et al.
patent: 5126375 (1992-06-01), Skidmore et al.
patent: 5225445 (1993-07-01), Skidmore et al.
patent: 5243076 (1993-09-01), Skidmore et al.
patent: 5283262 (1994-02-01), Mitchell et al.
patent: 5552438 (1996-09-01), Christensen, IV
patent: 5998428 (1999-12-01), Barnette et al.
patent: 69715 (1983-01-01), None
patent: 0069715 (1983-01-01), None
patent: 162576 (1985-11-01), None
patent: 220878 (1987-05-01), None
patent: 223410 (1987-05-01), None
patent: 286242 (1988-10-01), None
patent: 303465 (1989-02-01), None
patent: 317206 (1989-05-01), None
patent: 0416951 (1991-03-01), None
patent: 223671 (1991-11-01), None
patent: 0401966 (1994-01-01), None
patent: 0947498 (1999-10-01), None
patent: 2064336 (1981-06-01), None
patent: 2129691 (1984-05-01), None
patent: 2140800 (1984-12-01), None
patent: 2159151 (1985-11-01), None
patent: 2162842 (1986-02-01), None
patent: 2169265 (1986-07-01), None
patent: 2176476 (1986-12-01), None
patent: 2178965 (1987-02-01), None
patent: 220054 (1987-04-01), None
patent: 2242134 (1991-09-01), None
patent: WO 95/01170 (1995-01-01), None
patent: WO 99/16766 (1999-04-01), None
patent: WO 99/47505 (1999-09-01), None
patent: 0051599 (2000-09-01), None
patent: WO 01/13953 (2001-03-01), None
patent: 02066422 (2002-08-01), None
patent: 02070490 (2002-09-01), None
Fuji et al., “Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen,”J Pharmacol Exp Ther284(1):162 (1998).
Landells et al., “Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294A inhibits ex-vivo agonist-induced-cell activation,”Eur Resp J(/annu Cong Eur Resp Soc, Geneva) 12(Suppl.28) Abst P2393 (Sep. 1998).
McHale et al., “Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast,”Mol Pharmacol39:109-113 (1991).
Nicholson et al., “Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes,”Trends Pharmacol Sci12:19-27 (1991).
Thornber, “Isosterism and molecular modification in drug design,”Chemical Society Reviews:8(4)563-580 (1979).
Torphy et al., “Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis,”Mol. Pharmacol39:376-384 (1991).
U.S. Appl. No. 10/472,343, Filed Mar. 5, 2004, Keith Biggadike et al.
Dr. Meyer Magarici; “Riesgossobre broncodilatadors”; SVMS; Nov. 29, 2005.
Drug Bank Chemical Compound Query Result RE Salmeterol; 2000.
D. Iakovidis, et al.; “Synthesis and beta-andrenoceptor agonist properties of (+/−)-1-(3′,4′-dihydroxyphenoxy)-3-(3″,4″-dimethooxyphenyl)ethylamino-2-propanol hydrochloride, (+/−)-(RO363.HCl, and the (2S)-(−)-isomer”; European Journal of Medicinal Chemistry; Jun. 6, 1999; vol. 34, No. 6; pp. 539-548.
Robert Hett, et al.; “Enantioselective synthesis of salmeterol via asymmetric borane reduction”; Tetrahedron Letters; 1994; vol. 35, No. 50.
Biggadike Keith
Coe Diane Mary
Edney Dean David
Guntrip Stephen Barry
Halton Abigail
Carr Deborah D
Glaxo Group Limited
Smith Robert J.
LandOfFree
Methods using phenethanolamine derivatives for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods using phenethanolamine derivatives for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods using phenethanolamine derivatives for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3989321